ScreenerHero

TPSTTempest Therapeutics Inc. Common Stock

NAS · US · Healthcare · Biotechnology · tempesttx.com
1.040USD-2.80%Mkt Cap: 16.62M $P/E: —

Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of pero…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap16.62M $
Enterprise Value23.08M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-26.26M $
Revenue/Share—
Last Price1.040 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees4
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.84
PEG—
EV/EBITDA-1.27
EV/Revenue—
P/S—
P/B17.89
EPS (TTM)-3.49
EPS (Forward)-1.21
52W Range
0.84012% of range12.23
52W High12.23 USD
52W Low0.8401 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-393.85%
ROA-155.11%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-26.82M $
CapEx (TTM)—
FCF Margin—
FCF Yield-67.03%
Net Debt6.78M $
Net Debt/EBITDA-0.37
Balance Sheet
Debt/Equity1.22
Current Ratio0.38
Quick Ratio0.17
Book Value/Sh0.0570 USD
Cash/Share0.0490 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateDec 10, 2018
Splits
Last Split1:13
Split DateApr 9, 2025
Analyst Consensus
Rating—
Target (Mean)11.00 USD
Upside (mean)+957.7%
Target Range11.00 USD – 11.00 USD
# Analysts1
Ownership
Shares Out.15.98M
Float10.90M
Insiders31.78%
Institutions29.57%
Short Interest
Short Ratio1.5d
Short % Float3.57%
Short % Out.1.67%
Shares Short266.90K
Short (prev mo.)284.76K
Technical
SMA 501.050 (-1.0%)
SMA 2002.456 (-57.6%)
Beta—
S&P 52W Chg18.16%
Avg Vol (30d)261.66K
Avg Vol (10d)482.18K
Technical Indicators
RSI (14)50.1
MACD0.0105
MACD Signal-0.0127
MACD Hist.+0.0232
BB Upper1.214 USD
BB Middle0.9818 USD
BB Lower0.7492 USD
BB Width47.37%
ATR (14)0.0969 USD
Vol Ratio (20d)0.42x